Scott Rakestraw is Founder and Managing Director of The Branta Group LLC, a healthcare capital investment and strategic advisory firm known for taking an active entrepreneurship role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. Over the past 13 years, The Branta Group LLC and its family of companies have been instrumental in six successful Biotech IPOs, and the development and registration of several new biopharmaceutical medicines.
Prior to founding The Branta Group LLC, Dr. Rakestraw was a co-founder and Chief Business Officer of Orchid GeneShield, a subsidiary of Orchid BioSciences (Nasdaq: ORCH). Dr. Rakestraw served as General Manager of Biopharmaceuticals, Corporate Vice President of Business Development, and a member of the Board of Directors of Altus Pharmaceuticals, Inc (Nasdaq: ALTU). He started his career at DuPont Ventures where he held various roles as a venture co-founder and in business development, R&D, and marketing positions. Dr. Rakestraw received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. In his career, Dr. Rakestraw has worked to raise over $350 million in funding for ventures with which he has been directly involved as a founder or operating executive. He has served on the Board of Directors of Altus Pharmaceuticals and the CellScape Corporation; is a member of the Advisory Board of the Center for Surgery, Innovation & Bioengineering at the Massachusetts General Hospital/Harvard Medical School; is a member of the Chemical & Biomolecular Engineering Advisory Board of the University of Illinois and the Biomedical Engineering Advisory Board of Rutgers University; and has served as a judge for the Lemelson-MIT Student Prize for Inventorship.